Introduction
============

Lung cancer has the highest incidence and mortality among cancer cases worldwide, with 2.1 million new lung cancer cases and 1.8 million lung cancer deaths in 2018.[@b1-ott-12-2539] Accumulating evidence confirms that driven gene mutations play a critical role in the oncogenesis, personalized treatment, and prognosis assessment of lung cancer.[@b2-ott-12-2539] Clearly, how to detect gene mutations more precisely is the cornerstone. Tissue biopsy is traditionally regarded as the gold standard for detecting gene mutations; however, invasiveness and high requirements for operation restrict its wide application.[@b3-ott-12-2539]

Currently, liquid biopsy focusing on the detection of ctDNA, circulating tumor DNA (ctDNA) and circulating tumor cell (CTCs) in the blood of cancer patients has shed new light on real-time monitoring of therapy, identifying drug resistance and surveillance of disease progression.[@b4-ott-12-2539] ctDNA refers to the single- or double-stranded DNA released from TCs into the bloodstream,[@b5-ott-12-2539] while CTCs are the cells released by primary tumors into peripheral blood.[@b6-ott-12-2539] ctDNA and CTCs have paved new diagnostic avenues: collecting blood samples from cancer patients and isolating CTCs or extracting ctDNA, thereby obtaining a wealth of information on gene mutations, cancer phenotype, tumor-mutation burden, and drug resistance.[@b7-ott-12-2539] Noninvasiveness, predictability, and the same gene profile as primary tumors of ctDNA and CTCs have attracted enormous attention. However, which of the two competing biomarkers is better for detecting gene mutation in clinical practice is still a matter of debate. We undertook this meta-analysis to determine the diagnostic value of both ctDNA and CTCs in detecting different gene mutations in the blood of patients with lung cancer, including *EGFR*, *KRAS*, *ALK*, and *BRAF*, referred for tissue biopsy.

Methods
=======

Search strategy
---------------

An electronic literature search of PubMed, Embase, and Web of Science as of July 2018 was performed by two independent reviewers. Search items were: lung, pulmonary AND cancer, carcinoma, tumor, neoplasm AND mutation AND serum, plasma, circulating. Some potential studies were manually searched from relevant reference lists. Any disagreements were discussed, and if necessary a third author would arbitrate.

Inclusion and exclusion criteria
--------------------------------

Studies meeting all the following criteria were included: randomized controlled trials, cross-sectional studies, or cohort studies; focused on lung cancer patients; analyzed diagnostic value of CTCs or ctDNA for gene mutations; used tissue biopsy as the reference standard. Studies were excluded if they met one of the following criteria: reviews, letters, replies, case reports, conference abstracts, or animal experiments; articles not written in English; articles lacking essential information. Any disagreements were discussed.

Quality assessment
------------------

Two independent reviewers used RevMan version 5.3 to evaluate the quality of studies included based on the Quality Assessment of Diagnostic Accuracy Studies 2 tool.[@b8-ott-12-2539] Questions, including patient selection, index test, reference standard, and flow and timing, would be judged as "yes", "unclear", or "no" for each of the included studies.

Data extraction and management
------------------------------

Two independent authors extracted data: basic data (first author, publication year, countries/regions, number of patients, age, sex, blood volume, isolation methods, extraction methods, detection methods, and others) and diagnostic data (true positive, false positive, true negative and false negative). Disagreements were resolved by consensus.

Statistical analysis
--------------------

Meta-Disc version 1.4 was used to calculate pooled sensitivity, pooled specificity, AUC, positive-likelihood ratio and negative-likelihood ratio, each with a 95% CI. Forest plots and a summary receiver-operating characteristic (sROC) curves were plotted to present the results visually. Both threshold effect and nonthreshold effect were assessed to find the potential source of heterogeneity. If the *P*-value of the Spearman correlation coefficient was \<0.05, a threshold effect would exist. When the *P*-value of Cochran's *Q* test was \<0.10, a nonthreshold effect would be identified. Subgroup analyses were performed one subtypes of *EGFR* mutations, detection methods of liquid biopsy, and consistency of detection methods between liquid biopsy and tissue biopsy. Sensitivity analyses were also carried out to test the robustness of the main results by removing low-quality studies one by one. Quantitative evaluation of heterogeneity was evaluated by calculating *I*^2^, in accordance with the Cochrane Collaboration.[@b9-ott-12-2539]

Results
=======

Study characteristics
---------------------

A total of 47 of 4,283 studies were included in our analysis: nine[@b10-ott-12-2539]--[@b18-ott-12-2539] in the CTC group and 42[@b11-ott-12-2539],[@b13-ott-12-2539],[@b16-ott-12-2539],[@b17-ott-12-2539],[@b19-ott-12-2539]--[@b56-ott-12-2539] in the ctDNA group (four[@b11-ott-12-2539],[@b13-ott-12-2539],[@b16-ott-12-2539],[@b17-ott-12-2539] studies were in both groups; [Figure 1](#f1-ott-12-2539){ref-type="fig"}). Detected gene mutations in lung cancer were mainly in *EGFR*, *KRAS*, *ALK*, and *BRAF*. The volume of blood samples varied from 5.9 mL to 20.0 mL in the CTC group, and 1.5 mL to 20 mL in the ctDNA group. Detection methods for gene mutations were mainly sequencing and PCR in either liquid biopsy or tissue biopsy. The main characteristics of the CTC group and ctDNA group are shown in [Tables 1](#t1-ott-12-2539){ref-type="table"} and [2](#t2-ott-12-2539){ref-type="table"}, respectively.

Risk of bias
------------

In the CTC group, four studies were identified as low risk and one had unclear risk for the patient selection. Altogether, six publications were assessed as high risk and two had low risk on the index test. Low risk for reference standard was identified in all articles in this group. Four articles reported detailed information about flow and timing, assessed as low risk in this term. A total of four of nine, two of nine, and nine of nine articles had low concern regarding patient selection, index test, and reference standard, respectively. In the ctDNA group, 23 studies were assessed as low risk on patient selection, while two had unclear risk. There were 18 of 42 and 35 of 42 studies with low risk on the index test and reference standard, respectively. For flow and timing, 17 trials had low risk and the rest had high risk. A total of 23 of 42, 18 of 42, and 37 of 42 trials were identified as low concern for patient selection, index test, and reference standard, respectively. The risk of bias of the included studies is shown in [Figure 2](#f2-ott-12-2539){ref-type="fig"}.

Heterogeneity
-------------

Using Spearman's correlation coefficient, we found that a threshold effect existed in the ctDNA group when detecting *ALK* (*r*=1.000, *P*\<0.001). Cochran's *Q* indicated that a nonthreshold effect existed in the ctDNA group when testing *EGFR* (*χ*^2^=90.39, *P*\<0.001), *KRAS* (*χ*^2^=22.73, *P*=0.007), and *BRAF* (*χ*^2^=37.89, *P*\<0.001). However, no nonthreshold effects were found in the CTC group regarding the detection of *EGFR* or *KRAS*. sROC curves for the CTC and ctDNA groups are shown in [Figure 3](#f3-ott-12-2539){ref-type="fig"}.

Diagnostic accuracy
-------------------

For *EGFR*, pooled sensitivity, specificity, and AUC were 75.4% (95% CI 0.683--0.817), 85.2% (95% CI 0.729--0.934), and 88.5% (95% CI 0.778--0.993) in the CTC group and 67.1% (95% CI 0.647--0.695), 96.1% (95% CI 0.954--0.968), and 83.91% (95% CI 0.759--0.919) in ctDNA group, respectively. For *KRAS*, they were 38.7% (95% CI 0.266--0.519), 92.1% (95% CI 0.850--0.965), and 74.1% (95% CI 0.472--1.000) in the CTC group and 65.1% (95% CI 0.558--0.736), 95.5% (95% CI 0.932--0.972), and 91.0% (95% CI 0.804--1.000) in the ctDNA group, respectively. For *BRAF*, they were 31.3% (95% CI 0.141--0.532), 99.5% (95% CI 0.978--1.000), and 87.7% (95% CI 0--1.000) in the ctDNA group respectively. For *ALK*, only an sROC curve was plotted in ctDNA group, due to the threshold effect, and the ctDNA group had an AUC of 99.4% (95% CI 0.953--1.000). Summary plots of the CTC and ctDNA groups are shown in [Figures 4](#f4-ott-12-2539){ref-type="fig"} and [5](#f5-ott-12-2539){ref-type="fig"}, respectively.

Subgroup analyses
-----------------

Although we did not find a nonthreshold effect in the CTC group, we still performed subgroup analyses to identify potential influencing factors of CTCs when detecting different gene mutations.

### Subtypes of *EGFR* mutations

Seven subtypes of *EGFR* mutations -- Del19, L858R, T790M, L861Q, E20ins, G719X, and S768I -- were taken into consideration. For Del19, three and 18 studies were included in the CTC group and ctDNA groups, respectively. The CTC group and ctDNA group had summary sensitivity of 75.9% (95% CI 0.654--0.845) and 79.0% (95% CI 0.767--0.812), respectively. For L858R, the CTC group included four articles, while the ctDNA group had 20 studies. Pooled sensitivity was 62.2% (95% CI 0.501--0.732) in the CTC group and 76.7% (95% CI 0.731--0.800) in the ctDNA group. For T790M, the CTC group had slightly higher sensitivity than the ctDNA group (63.3% versus 61.2%). No significant findings were observed to explain the nonthreshold effect in the ctDNA group when detecting Del19, L858R, and T790M. However, a nonthreshold effect was not observed in ctDNA group when testing L861Q (*χ*^2^=0.18, *P*=0.670), E20ins (*χ*^2^=1.53, *P*=0.467), G719X (*χ*^2^=0.09, *P*=0.765), or S768I (*χ*^2^=0.27, *P*=0.606).

### Detection methods of CTCs or ctDNA

The CTC group had higher sensitivity than the ctDNA group whether applying sequencing (85.1% versus 75.6%) or PCR (72.1% versus 67.2%) to detect *EGFR*. When sequencing was used to test *KRAS*, ctDNA showed excellent performance, with sensitivity of 66.9% (95% CI 0.535--0.786). When *KRAS* was detected by PCR, sensitivity was 30.8% (95% CI 0.170--0.476) and 66.9% (95% CI 0.535--0.786) in the CTC and ctDNA groups, respectively. When sequencing was employed to detect *BRAF*, sensitivity was 87.5% (95% CI 0.473--0.997) in the ctDNA group. Heterogeneity brought by nonthreshold effects was not found in the ctDNA group (*χ*^2^=0.086, *P*=0.872) when detecting *KRAS* (*χ*^2^=0.086, *P*=0.872) or *BRAF* (*χ*^2^=0.62, *P*=0.892) by sequencing.

Consistency of detection methods between liquid biopsy and tissue biopsy
------------------------------------------------------------------------

If the same method were employed for liquid biopsy and tissue biopsy to test gene mutations, this would be grouped in the consistent subgroup and otherwise the inconsistent subgroup. CTCs and ctDNA showed similar capacity for testing *EGFR* when using the consistent method with tissue biopsy. Higher sensitivity was identified when using inconsistent methods to detect ctDNA for *KRAS* (81.5%, 95% CI 0.673--0.914), as well as *BRAF* (100%, 95% CI 0.398--1.000). Meanwhile, we did not find any nonthreshold effect in the ctDNA group when inconsistent methods were used for *BRAF* analysis (*χ*^2^=0.62, *P*=0.431). Results of subgroup analyses are shown in [Table 3](#t3-ott-12-2539){ref-type="table"}.

Sensitivity analyses
--------------------

No significant results were identified in sensitivity analyses.

Discussion
==========

We found that ctDNA and CTCs had similar performance when detecting *EGFR* and its detailed subtypes. However, ctDNA showed great strength for detecting *KRAS* and *ALK*. Subgroup analyses indicated that detection method had a great impact on the diagnostic capacity of ctDNA and CTCs.

CTCs had slightly higher sensitivity than ctDNA when detecting *EGFR*, which has been supported by some researchers.[@b14-ott-12-2539] This may partly be attributed to the low abundance of ctDNA in peripheral blood. Although the level of ctDNA in cancer individuals was much higher than normal, it still accounted for \<1% of cell-free DNA.[@b57-ott-12-2539] ctDNA quantity is prone to be only one genome per 5 mL plasma in the early stage of cancer.[@b58-ott-12-2539] Therefore, the effective capture of ctDNA is still technically challenging, though Punnoose et al[@b16-ott-12-2539] held the opposite opinion that ctDNA might outperform CTCs for *EGFR* detection. Treatment status may explain this inconsistency to some extent. The proportion of patients receiving treatment in their trial was higher than that in ours, while therapy can decrease CTC counts more effectively and increase the difficulty of detection.

For *KRAS*, ctDNA showed excellent diagnostic ability. Shen et al[@b59-ott-12-2539] conducted a meta-analysis and came to a different conclusion than us. They included two studies that we excluded during literature screening.[@b60-ott-12-2539],[@b61-ott-12-2539] One did not describe clearly whether they analyzed the value of CTCs or ctDNA,[@b60-ott-12-2539] while another extracted RNA from CTCs for detection.[@b61-ott-12-2539] Great heterogeneity may exist between these two studies, which might have impacted the final results. Limited articles restricted us in analyzing the value of CTCs for *ALK* detection. In the ctDNA group, pooled sensitivity and specificity were not yielded, because of a threshold effect, while sROC curves and AUC indicated the high value of ctDNA in testing *ALK*, in line with other investigators.[@b62-ott-12-2539] For *BRAF*, the value of CTCs was not explored, due to limited studies. ctDNA had low sensitivity, contrary to the results of the following two studies.[@b63-ott-12-2539],[@b64-ott-12-2539] Guibert et al analyzed only six samples, and did not regard tissue biopsy as the reference standard.[@b63-ott-12-2539] Different sample size and reference standard were considered as the reasons for the discrepancy. Thierry et al[@b64-ott-12-2539] concentrated on the value of ctDNA in colorectal cancer. Different *BRAF* mutational load between lung cancer and colorectal cancer may have led to the difference in results. CTCs and ctDNA showed great variance in performance for different gene mutations and different detection kits, and methods may have contributed also.

Subgroup analyses
-----------------

In view of individual treatment, analyzing detailed *EGFR*-mutation subtypes is critical. Therefore, we focused on the value of CTCs and ctDNA in testing detailed *EGFR*-mutation subtypes. We found that ctDNA had slightly higher accuracy for del19 and L858R. Different-accuracy detection methods may have an impact. More sensitive methods, including droplet digital PCR and circulating single-molecule amplification and resequencing technology, were used in the ctDNA group. For T790M, which is largely responsible for resistance to first-generation or irreversible tyrosine-kinase inhibitors,[@b65-ott-12-2539] CTCs and ctDNA showed similar diagnostic performance. This was consistent with other researchers.[@b14-ott-12-2539],[@b66-ott-12-2539]

Various detection methods had great influence on the accuracy of CTCs and ctDNA; therefore, subgroup analyses based on different detection methods were necessary. In both the CTC and ctDNA groups, sequencing outperformed other detection methods, whether detecting *EGFR*, *KRAS*, or *BRAF*. To our knowledge, the low limit of detection and ability to determine lower mutant-allele frequency confers excellent capacity upon sequencing.[@b67-ott-12-2539],[@b68-ott-12-2539] Although PCR is a cost-effective technology, it can analyze only limited genomic loci and has a high requirement for mutant-allele frequency.[@b58-ott-12-2539] Notably, digital PCR, as distinct from traditional PCR, is considered a very sensitive detection method,[@b69-ott-12-2539],[@b70-ott-12-2539] and our study also confirmed this (data not shown).

Strengths and limitations
-------------------------

Although several meta-analyses were carried out, they focused on the diagnostic value of ctDNA or CTCs in only one type of gene mutation.[@b59-ott-12-2539],[@b71-ott-12-2539],[@b72-ott-12-2539] This is the first comprehensive study to analyze the diagnostic value of both ctDNA and CTCs for various gene mutations in lung cancer. We found that ctDNA might have better diagnostic performance than CTCs; however, clinical application of ctDNA for gene-mutation detection in lung cancer still needs to consider cost, operation process, and other factors. Meanwhile, subgroup analyses based on detailed *EGFR*-mutation subtypes, the detection methods of CTCs or ctDNA, and consistency of detection methods between liquid biopsy and tissue biopsy, were also carried out to explore potential influencing factors. However, other gene mutations in lung cancer, such as *PIK3CA* and *TP53*, were not included in our study, due to limited literature, which is the subjects of further investigations.

Conclusion
==========

For lung cancer, ctDNA showed equivalent diagnostic ability as CTCs when detecting *EGFR* and its subtypes, and excellent performance for *KRAS*- and *ALK*-mutation detection. In general, ctDNA might be more suitable for clinical application of gene-mutation detection in lung cancer. Furthermore, our study also implies the significance of effective extraction kits and detection methods for improving the diagnostic capacity of ctDNA and CTCs.
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Summary plots of sensitivity and specificity of the ctDNA group.

**Abbreviations:** CtDNA, circulating tumor DNA; EGFR, epidermal growth factor receptor; TP, true positive; FP, false positive; TN, true negative; FN, false negative; KRAS, kirsten rat sarcoma viral oncogene homolog; BRAF, B-Raf protooncogene, serine/threonine kinase.
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###### 

Characteristics of studies included in the CTC group

  Study                                                          Country          n     ADC   Smokers   F/M      TNM (l-IV)   Mutation                    *CTC*              Tissue                     
  -------------------------------------------------------------- ---------------- ----- ----- --------- -------- ------------ --------------------------- ------------------ ------------------- ------ ----------------------------------------------
  Breitenbuecher et al                                           Germany          8     NA    NA        5/3      NA           *EGFR*                      Peripheral blood   Sanger sequencing   NA     Sanger sequencing
  Freidin et al[\*](#tfn1-ott-12-2539){ref-type="table-fn"}      UK               82    27    NA        NA       NA           *KRAS*                      Plasma             Cold PCR-HRM        FFPE   Therascreen, Cobas tissue test, cold PCR-HRM
  Guibert et al                                                  France           32    32    NA        1 1/21   NA           *KRAS*                      Plasma             dd-PCR              FFPE   RT-PCR, HRM
  He et al[\*](#tfn1-ott-12-2539){ref-type="table-fn"}           China            120   120   96        42/78    0/0/24/96    *EGFR*                      Plasma             dd-PCR              NA     dd-PCR
  Maheswaran et al                                               USA              27    25    NA        15/12    NA           *EGFR*                      Plasma             ARMS                FFPE   Sanger sequencing, ARMS
  Marchetti et al                                                Italy            37    NA    NA        NA       NA           *EGFR*                      NA                 Ultradeep NGS       NA     Ultradeep NGS
  Punnoose et al[\*](#tfn1-ott-12-2539){ref-type="table-fn"}     USA, Australia   41    NA    NA        NA       NA           *EGFR, KRAS*                Plasma             TaqMan              NA     TaqMan
  Sundaresan et al[\*](#tfn1-ott-12-2539){ref-type="table-fn"}   USA              40    NA    NA        26/14    0/0/6/34     *EGFR^T79m^*                Plasma             Direct sequencing   NA     NA
  Yeo et al                                                      Singapore        7     NA    NA        6/1      NA           *EGFR^L858R^, EGFR^T79m^*   Plasma             Direct sequencing   NA     NA

**Note:**

ln both the CTC and ctDNA groups, with CTC and ctDNA data analyzed in two independent articles.

**Abbreviations:** CTC, circulating tumor cell; ADC, adenocarcinoma; NA, not available; HRM, high-resolution melting; FFPE, formalin-fixed, paraffin-embedded; dd, droplet digital; RT, reverse transcription; ARMS, amplificati on-refractory mutation system; NGS, next-generation sequencing; ctDNA, circulating tumor DNA.

###### 

Characteristics of articles included in the ctDNA group

  Study                                                                             Country                   n       ADC   Smoker   F/M       TNM (I--IV)    Mutation                                                                        ctDNA           Tissue                                                                 
  --------------------------------------------------------------------------------- ------------------------- ------- ----- -------- --------- -------------- ------------------------------------------------------------------------------- --------------- ------------------------------------------------------ --------------- ------------------------------------------------------
  Arriola et al[@b19-ott-12-2539]                                                   Spain                     154     112   127      39/115    0/0/18/136     *EGFR*                                                                          Plasma          PNA clamp, fragment- length analysis                   NA              Therascreen
  Chai et al[@b20-ott-12-2539]                                                      China                     61      58    NA       34/27     0/0/21/40      *EGFR*                                                                          Plasma          cSMART                                                 FFPE            ARMS
  Del et al[@b21-ott-12-2539]                                                       Italy                     33      NA    11       20/13     0/0/1/32       *EGFR*^T790M^, *KRAS*                                                           Plasma          dd-PCR                                                 NA              dd-PCR, standard sequencing
  Douillard et al[@b22-ott-12-2539]                                                 13 countries              1,060   NA    NA       NA        NA             *EGFR*                                                                          Plasma          ARMS                                                   NA              ARMS
  Freidin et al[@b11-ott-12-2539],,[\*](#tfn3-ott-12-2539){ref-type="table-fn"}     UK                        82      27    NA       NA        NA             *KRAS*                                                                          Plasma          Cold PCR/HRM                                           FFPE            Therascreen, Cobas tissue test, cold PCR/HRM assay
  Gautschi et al[@b23-ott-12-2539]                                                  USA                       180     79    125      55/125    15/11/64/91    *KRAS*                                                                          Plasma          RFLP-PCR                                               FFPE            RFLP-PCR
  Gu et al[@b24-ott-12-2539]                                                        China                     47      47    NA       26/21     0/0/11/36      *EGFR*                                                                          Plasma          d-PCR                                                  FFPE            ARMS
  Guo et al[@b25-ott-12-2539]                                                       China                     20      20    8        7/13      0/0/5/15       *EGFR*                                                                          Plasma          Tag sequencing                                         FFPE            ARMS
  Han et al[@b26-ott-12-2539]                                                       South Korea               208     164   131      72/136    0/0/15/193     *EGFR*, *KRAS*                                                                  Plasma          PNA clamp-assisted melting curve                       FFPE            PNA clamp-assisted melting curve
  He et al[@b27-ott-12-2539]                                                        China                     134     101   63       49/85     NA             *EGFR*                                                                          Plasma          Mutant-enriched PCR                                    NA              Direct sequencing
  He et al[@b28-ott-12-2539]                                                        China                     200     200   188      54/146    0/0/44/156     *EGFR*                                                                          Plasma          dd-PCR                                                 NA              dd-PCR
  He et al[@b13-ott-12-2539],[\*](#tfn3-ott-12-2539){ref-type="table-fn"}           China                     120     120   96       42/78     0/0/24/96      *EGFR*                                                                          Plasma          dd-PCR                                                 NA              dd-PCR
  Jenkins et al[@b29-ott-12-2539]                                                   UK                        551     NA    NA       NA        NA             *EGFR*^del19^, *EGFR*^L858R^, *EGFR*^T790M^                                     Plasma          Cobas plasma test                                      NA              Cobas tissue test
  Kim et al[@b30-ott-12-2539]                                                       South Korea               102     NA    31       62/40     0/0/0/102      *EGFR*^del19^, *EGFR*^L858R^                                                    Plasma          PNA clamp-assisted melting curve                       FFPE            PNA clamp-assisted melting curve
  Kobayashi et al[@b31-ott-12-2539]                                                 Japan                     15      NA    7        10/5      NA             *EGFR*^T790M^                                                                   Plasma, serum   Cobas plasma test                                      NA              PNA-LNA clamp, Cobas tissue test
  Lee et al[@b32-ott-12-2539]                                                       South Korea               57      57    16       39/18     0/0/0/57       *EGFR*^del19^, *EGFR*^L858R^                                                    Plasma          PNA clamp-assisted melting curve                       NA              Sanger sequencing, PNA clamp
  Ma et al[@b33-ott-12-2539]                                                        China                     157     157   70       59/98     0/0/32/125     *EGFR*                                                                          Plasma          ARMS                                                   FFPE            ARMS
  Mao et al[@b34-ott-12-2539]                                                       China                     40      25    21       13/27     0/0/13/27      *EGFR*, *KRAS*, *ALK*, *BRAF*                                                   Plasma          Targeted sequencing                                    FFPE            ARMS, FISH
  Newman et al[@b35-ott-12-2539]                                                    USA                       66      NA    NA       NA        NA             *EGFR*                                                                          Plasma          iDES-enhanced CAPP sequencing                          FFPE            iDES-enhanced CAPP sequencing
  Pasquale et al[@b36-ott-12-2539]                                                  Italy                     96      84    64       36/60     NA             *EGFR*                                                                          Plasma          Therascreen, PNA clamp                                 NA              Therascreen
  Pecuchet et al[@b37-ott-12-2539]                                                  France                    109     NA    73       60/49     0/0/12/97      *EGFR*, *KRAS*, *ALK*, *BRAF*                                                   Plasma          Ultradeep-targeted NGS                                 FFPE            Ultradeep-targeted NGS
  Punnoose et al[@b16-ott-12-2539],[\*](#tfn3-ott-12-2539){ref-type="table-fn"}     USA, Australia            41      NA    NA       NA        NA             *EGFR*, *KRAS*, *BRAF*                                                          Plasma          TaqMan                                                 NA              TaqMan
  Rachiglio et al[@b38-ott-12-2539]                                                 Italy                     44      NA    NA       21/23     0/0/1/43       *EGFR*                                                                          Plasma          Targeted sequencing                                    NA              Targeted sequencing
  Reck et al[@b39-ott-12-2539]                                                      European nations, Japan   1,288   952   1,035    421/867   NA             *EGFR*                                                                          Plasma          Others[\*\*](#tfn4-ott-12-2539){ref-type="table-fn"}   NA              Others[\*\*](#tfn4-ott-12-2539){ref-type="table-fn"}
  Schwaederle et al[@b40-ott-12-2539]                                               USA                       88      88    50       58/30     NA             *EGFR*                                                                          Plasma          Digital sequencing                                     NA              NGS
  Sun et al[@b41-ott-12-2539]                                                       China                     55      NA    NA       NA        NA             *EGFR*                                                                          Plasma          MST-PCR                                                FFPE            Direct sequencing
  Sundaresan et al[@b17-ott-12-2539],[\*](#tfn3-ott-12-2539){ref-type="table-fn"}   USA                       40      NA    NA       26/14     0/0/6/34       *EGFR*^T790M^                                                                   Plasma          Cobas plasma test                                      NA              NA
  Thompson et al[@b42-ott-12-2539]                                                  USA                       102     83    65       69/33     0/2/2/98       *EGFR*, *KRAS*, *BRAF*                                                          Plasma          Paired-end sequencing                                  NA              NGS
  Thress et al[@b43-ott-12-2539]                                                    USA                       38      NA    NA       NA        NA             *EGFR*^L858R^, *EGFR*^T790M^                                                    Plasma          ARMS, dd-PCR, d-PCR, Cobas plasma test                 FFPE            Cobas tissue test
  Uchida et al[@b44-ott-12-2539]                                                    Japan                     288     274   NA       119/169   64/46/26/146   *EGFR*                                                                          Plasma          PNA-LNA clamp                                          NA              PNA-LNA clamp
  Veldore et al[@b45-ott-12-2539]                                                   India                     132     113   77       40/92     NA             *EGFR*                                                                          Plasma          NGS                                                    FFPE            RT-PCR
  Wang et al[@b46-ott-12-2539]                                                      China                     108     102   37       53/55     0/0/3/5        *EGFR*                                                                          Plasma          dd-PCR                                                 FFPE            ARMS
  Wang et al[@b47-ott-12-2539]                                                      China                     224     216   NA       NA        47/49/60/68    *EGFR*                                                                          Plasma          qRT-PCR                                                FFPE            qPCR
  Wang et al[@b48-ott-12-2539]                                                      China                     287     249   64       104/83    0/0/31/156     *EGFR*                                                                          Plasma          DHPLC                                                  FFPE            DHPLC
  Wang et al[@b49-ott-12-2539]                                                      China                     103     103   33       55/48     0/0/25/78      *EGFR*,[\*\*\*](#tfn5-ott-12-2539){ref-type="table-fn"} *KRAS*, *ALK*, *BRAF*   Plasma          cSMART                                                 FFPE            ARMS
  Wu et al[@b50-ott-12-2539]                                                        China                     45      42    NA       22/23     0/0/2/43       *EGFR*^del19^, *EGFR*^L858R^, *EGFR*^T790M^                                     Plasma          ARMS                                                   NA              ARMS
  Xu et al[@b51-ott-12-2539]                                                        China                     51      43    19       20/31     0/0/6/45       *EGFR*^del19^, *EGFR*^L858R^                                                    Plasma          DHPLC, MEL, ARMS                                       NA              ARMS
  Yang et al[@b52-ott-12-2539]                                                      China                     73      73    20       44/29     NA             *EGFR*                                                                          Plasma          ddPCR                                                  NA              dd-PCR
  Yao et al[@b53-ott-12-2539]                                                       China                     39      34    10       20/19     0/0/8/31       *EGFR*, *KRAS*                                                                  Plasma          Targeted sequencing                                    Fresh or FFPE   Targeted sequencing
  Yoshida et al[@b54-ott-12-2539]                                                   Japan                     31      NA    NA       NA        NA             *EGFR*^del19^, *EGFR*^L858R^, *EGFR*^T790M^                                     Plasma          PNA-LNA clamp                                          NA              PNA-LNA clamp
  Zheng et al[@b55-ott-12-2539]                                                     China                     117     108   29       71/46     0/0/5/91       *EGFR*^T790M^                                                                   Plasma          dd-PCR                                                 NA              ARMS
  Zhou et al[@b56-ott-12-2539]                                                      China                     447     387   220      201/246   50/22/70/303   *EGFR*                                                                          Plasma          ARMS                                                   NA              ARMS

**Notes:**

In both the CTC and ctDNA groups, with CTC and ctDNA data analyzed in two independent articles;

more than ten detection methods, eg, DNA sequencing and fragment length analysis, used in this study;

*EGFR*^del19^, *EGFR*^L858R^, *EGFR*^T790M^, *EGFR*^L861Q^, *EGFR*^E20ins^, *EGFR*^G719X^, and *EGFR*^S768I^ analyzed in this study.

**Abbreviations:** ctDNA, circulating tumor DNA; ADC, adenocarcinoma; NA, not available; cSMART, circulating single-molecule amplification and resequencing technology; FFPE, formalin-fixed, paraffin-embedded; ARMS, amplification-refractory mutation system; dd, droplet digital; HRM, high-resolution melting; RFLP, restriction fragment-length polymorphism; d-PCR, digital PCR; FISH, fluorescence in situ hybridization; NGS, next-generation sequencing; MST, microbial source tracking; qRT, quantitative real-time; DHPLC, denaturing high-performance liquid chromatography; MEL, ME liquid.

###### 

Results of subgroup analyses

                                  n    *χ*^2^   *P*-value   Sensitivity (95% CI)   *I*^2^   Specificity (95% CI)   *I*^2^
  ------------------------------- ---- -------- ----------- ---------------------- -------- ---------------------- --------
  **CTC**                                                                                                          
  *EGFR*-mutation types                                                                                            
   del19 subgroup                 3    1.00     \<0.001     75.9% (0.654--0.845)   85.2%    98.0% (0.917--0.999)   66.4%
   L858R subgroup                 4    6.01     0.111       62.2% (0.501--0.732)   0        98.7% (0.929--1.000)   45.1%
   T790M subgroup                 3    2.02     0.365       63.3% (0.353--0.860)   60.8%    75.0% (0.522--0.908)   57.5%
  Detection methods                                                                                                
  * EGFR* sequencing              2    0.15     0.695       85.1% (0.717--0.938)   0        50.0% (0.013--0.987)   0
  * EGFR* PCR                     3    1.85     0.396       72.1% (0.633--0.799)   56.1%    88.0% (0.757--0.955)   92.1%
  * KRAS* PCR                     2    0.84     0.358       30.8% (0.170--0.476)   50.8%    97.6% (0.874--0.999)   62.5%
  Consistent or inconsistent                                                                                       
  * EGFR* consistent              4    2.83     0.418       69.8% (0.611--0.775)   41.0%    97.7% (0.877--0.999)   55.4%
  * KRAS* consistent              2    0        0.963       42.0% (0.227--0.632)   76.6%    90.9% (0.836--0.956)   84.6%
  * KRAS* inconsistent            2    1.67     0.197       42.0% (0.289--0.559)   40.1%    87.5% (0.764--0.946)   0
  **ctDNA**                                                                                                        
  *EGFR*-mutation types                                                                                            
   del19 subgroup                 19   143.29   \<0.001     79.0% (0.767--0.812)   91.5%    95.8% (0.948--0.967)   93.1%
   L858R subgroup                 20   58.54    \<0.001     76.7% (0.731--0.800)   70.2%    97.2% (0.964--0.979)   70.9%
   T790M subgroup                 17   31.41    0.012       61.2% (0.570--0.654)   41.3%    92.7% (0.909--0.943)   86.7%
   L861Q subgroup                 2    0.18     0.670       100% (0.292--1.000)    0        99.4% (0.966--1.000)   50.5%
   E20ins subgroup                3    1.53     0.467       83.3% (0.359--0.996)   24.1%    98.3% (0.964--0.994)   0.6%
   G719X subgroup                 2    0.09     0.765       100% (0.398--1.000)    0        97.4% (0.935--0.993)   71.5%
   S768I subgroup                 2    0.27     0.606       75.0% (0.061--1.000)   0        99.5% (0.979--1.000)   21.0%
  Detection methods                                                                                                
  * EGFR* sequencing              10   24.13    0.004       75.6% (0.698--0.807)   59.0%    95.8% (0.93--0.977)    78.5%
  * EGFR* PCR                     15   45.27    \<0.001     67.2% (0.643--0.701)   91.0%    97.2% (0.965--0.979)   83.3%
  * EGFR* others                  3    6.15     0.046       54.5% (0.469--0.621)   55.7%    89.7% (0.86--0.926)    83.9%
  * KRAS* sequencing              6    7.37     0.195       66.9% (0.535--0.786)   0        97.8% (0.954--0.991)   87.9%
  * KRAS* PCR                     4    8.05     0.045       63.3% (0.477--0.772)   91.0%    84.5% (0.742--0.918)   41.5%
  * KRAS* others                  2    8.92     0.003       80.0% (0.631--0.916)   90.2%    91.2% (0.861--0.949)   38.8%
  * BRAF* sequencing              4    0.62     0.892       87.5% (0.473--0.997)   0        99.7% (0.981--1.000)   27.1%
  Consistent or inconsistent                                                                                       
  * EGFR* consistent              16   62.81    \<0.001     69.3% (0.664--0.720)   88.5%    95.7% (0.945--0.967)   88.2%
  * EGFR* inconsistent            10   23.25    0.006       74.6% (0.682--0.804)   65.4%    95.5% (0.933--0.972)   78.6%
  * KRAS* consistent              7    15.14    0.019       62.8% (0.519--0.727)   82.5%    92.1% (0.886--0.949)   79.9%
  * KRAS* inconsistent            4    8.21     0.042       81.5% (0.673--0.914)   73.6%    95.0% (0.908--0.976)   90.2%
  * BRAF* consistent              2    10.06    0.002       13.2% (0.023--0.364)   84.7%    99.5% (0.957--1.000)   79.9%
  * BRAF* inconsistent subgroup   2    0.62     0.431       100% (0.398--1.000)    0        99.3% (0.961--1.000)   61.7%

**Abbreviations:** CTC, circulating tumor cell; CtDNA, circulating tumor DNA.

[^1]: These authors contributed equally to this work
